HER2-negative Breast Cancer trials recruiting in Florida

All HER2-negative Breast Cancer trials nationally

Cities in Florida

Recruiting trials in Florida

• A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
  NCT06568692 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Florida: Miami, Tampa
• A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
  NCT06999187 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Florida: Orlando, Sarasota
• A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
  NCT05824975 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Florida: Jacksonville
• BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
  NCT06120283 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Florida: Lake Mary
• Breast Re-irradiation After Second Ipsilateral Lumpectomy
  NCT06867484 · Phase: Not applicable (e.g. observational or device study) · Ages: 40 Years and older · Sex: Female · Florida: Boca Raton, Miami
• DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs
  NCT06176261 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Florida: Miami
• DecipHER Trial - DC1 Tx for Early-Stage TNBC and ER Low Positive Breast Cancer
  NCT05504707 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Florida: Tampa
• DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Breast Cancer Patients
  NCT06388122 · Phase: Not specified · Ages: 18 Years and older · Sex: Female · Florida: Jacksonville
• First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
  NCT05216432 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Florida: Orlando, Plantation
• I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
  NCT01042379 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Florida: Tampa
• PRE-ISPY Phase I/II Oncology Platform Program
  NCT05868226 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Florida: Tampa
• Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer
  NCT05508906 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Florida: Orlando
• Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
  NCT06982521 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Florida: Altamonte Springs, Fort Myers, Palm Bay
• Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer
  NCT05467891 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Florida: Orlando
• The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
  NCT04585750 · Phase: Phase 1, Phase 2 · Ages: 12 Years and older · Sex: All (male and female) · Florida: Miami, Orlando, Port Charlotte